A Novel Dual-targeting OX40L and IL-13 Bispecific Antibody with Synergistic Effect for Atopic Dermatitis Treatment 2255160
The anti—OX40/IL-13 bispecific exhibited enhanced suppression of Th1, Th2, Th17, and Th22 inflammatory responses both in vitro and in vivo, indicating synergistic immunomodulation through dual target engagement.